絞り込み

17431

広告

Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017.

著者 Lutsey PL , Walker RF , MacLehose RF , Alonso A , Adam TJ , Zakai NA
Res Pract Thromb Haemost.2019 Oct ; 3(4):668-673.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (44view , 0users)

Full Text Sources

Direct oral anticoagulants (DOACs), namely rivaroxaban, apixaban, dabigatran, and edoxaban, are now included together with warfarin as standards of care for the primary treatment of venous thromboembolism (VTE). The extent to which the DOACs have been adopted since receiving US Food and Drug Administration (FDA) approval is unknown.
PMID: 31624786 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード